Edison Oncology Lead Programs
Our programs consist of biomarker-driven, small molecule, targeted drug candidates
EO-3001
ARID1a Targeted Therapy
Ovarian Clear Cell Cancer Carcinoma
& Solid Tumors
Pre-Clinical
Phase 1-2 Clincal Trials
Registration Trial
FDA Approval
EO-4426
Tezacitabine
Solid Tumors & Hematologic Malignancies
Pre-Clinical
Phase 1-2 Clincal Trials
Registration Trial
FDA Approval
OROTECAN®
(oral irinotecan HCI)
Pediatric Sarcomas
& Adult Malignancies
Pre-Clinical
Phase 1-2 Clincal Trials
Registration Trial
FDA Approval
Edison Oncology Partnered Programs
Apollomics licensed global rights (exChina/HK/Taiwan)
EO-1001
Pan-ErbB inhibitor
Advanced/metastatic ErbB-positive solid tumors, including EGFR+, NSCLC, HER2+ breast cancer, glioblastoma, and others
Pre-Clinical
Phase 1-2 Clincal Trials
Registration Trial
FDA Approval
Our Pipeline – Lead Programs
Orotecan®:
Orotecan is a novel, patented oral formulation of irinotecan, a major cancer therapy. Orotecan has been developed in collaboration with leading cancer clinicians to improve tolerability and patient compliance in the treatment of rare childhood tumors, with an opportunity to expand into major adult cancers.
EO3001 - mitochondrial targeting agent:
EO3001 was studied in prior clinical trials involving more than 1,000 cancer patients. We have identified biomarker-circumscribed orphan cancer population that we believe will benefit from treatment with EO3001. Edison Oncology has filed new patents related to these discoveries.
EO1001:
Edison Oncology is planning clinical trials of EO-4426 in solid tumors and hematologic malignancies in 1H 2026.
Our Pipeline – Partner Programs
EO1001:
EO1001 is partnered with Apollomics Inc. EO1001 is a novel, irreversible pan-erbB inhibitor with excellent brain penetration offering the potential for improved efficacy for non-small cell lung cancer (NSCLC) and breast cancer patients with treatment-resistant disease, including brain metastasis. Edison Oncology has initiated the regulatory filing process and plans to initiate human clinical trials with EO1001 during 2021
Business Development Opportunities
Please contact us if you are interested in business opportunities.
Careers
Join our team! Visit our website to view available opportunities and apply now.
Investors
All prospective investors, please contact us if you are interested in learning more.